Today’s selection examines how immune responses during pregnancy may prevent the loss of early childhood memories, the narrowing gap between male and female autism diagnoses over time, and recent integrity concerns in federal policy and clinical research (Blog Name: Living on the Spectrum).
Immune Activation Linked to Early Memory Retention in Mice
Research Findings
A study led by Tomás Ryan at Trinity College Dublin found that male mice in a maternal immune activation (MIA) model do not experience "infantile amnesia." While neurotypical infant mice typically lose access to memories formed during infancy within a week, those exposed to immune triggers in utero retain them. This "excess of memory" suggests that neurodevelopmental differences can fundamentally alter how the brain manages and forgets early information.
Biological Mechanisms
The research team identified microglia, the brain's resident immune cells, as the primary mediators of this memory retention. MIA male mice showed a higher density of dendritic spines and more specialized memory cells in the dentate gyrus. By deactivating microglia or blocking specific receptors like CX3CR1, researchers could alter memory persistence. The study also highlighted the enzyme Rac1, which is linked to several autism-associated genes, as a critical factor in preventing the natural forgetting process.
Significance & Limitations
This research provides a new framework for understanding how early brain development impacts learning trajectories. However, some experts question the specific role of microglia in synaptic pruning during this stage and note that the study relied on minocycline, a drug with effects that may not be entirely specific to microglia. The findings suggest that early memories in typical development are not deleted but become "latent," whereas the MIA state keeps them accessible.
Autism Diagnosis Gender Gap Narrows with Age
Shift in Diagnosis Rates
A study of 2.7 million children in Sweden shows that the traditional male-to-female ratio in autism diagnoses drops significantly as individuals age. While boys are three times more likely than girls to receive a diagnosis before age 10, the ratio falls to 1.2-to-1 by age 20. Data from 2022 suggests that for the youngest cohorts, the cumulative ratio may reach parity—a 1:1 balance—by the time they reach adulthood.
Reasons for Delayed Identification
Researchers attribute the later diagnosis of girls to "masking" or "camouflaging," where autistic traits are hidden to fit social expectations. These strategies often become unsustainable during adolescence when social environments become more complex. Additionally, girls may present with advanced language skills or better eye contact than autistic boys, leading to "diagnostic overshadowing" where their traits are misattributed to other conditions.
Future Implications
The findings suggest that previous estimates of sex differences in autism were likely inflated by diagnostic bias. The study also found that the sex ratio is consistently lower when autism co-occurs with an intellectual disability. Experts emphasize the need for more diverse research populations to ensure that personalized identification practices account for these shifting diagnostic trends.
Concerns Over New Appointments to U.S. Federal Autism Committee
Policy Shift Concerns
The U.S. Department of Health and Human Services recently appointed 21 new members to the Interagency Autism Coordinating Committee (IACC), sparking criticism from the scientific community. The new roster excludes all returning members and federal agency representatives. Critics argue this loss of institutional knowledge may prevent the committee from effectively coordinating national autism policy and research.
Scientific Integrity and Representation
The appointments include individuals who have promoted discredited theories, such as the link between vaccines and autism. Research leaders fear this shift will divert federal focus and funding toward unproven treatments rather than evidence-based science. Furthermore, autistic representation on the committee decreased from seven members to two, leading self-advocates to worry that the committee will prioritize "cures" over community support and quality-of-life improvements.
Retraction of Major Autism Drug Trial Due to Data Errors
Core Issues
The European Journal of Pediatrics retracted the largest clinical trial to date on leucovorin (folinic acid) as an autism treatment. The journal cited data inconsistencies and statistical errors that undermined the study's conclusions. Discrepancies between data tables led to a total loss of confidence in the reported results of the trial, which involved 77 children.
Clinical Misuse
The study inappropriately used the Childhood Autism Rating Scale (CARS) to measure quantitative changes in symptoms. CARS is a tool designed specifically to confirm a diagnosis, not to track progress or response to medication. Experts point out that the overall evidence for folinic acid remains weak, often characterized by small sample sizes and poor research design, including inadequate blinding procedures.
Podcast Transcript
Aaron: Hello everyone, welcome to the podcast. I am Aaron.
Jamie: And I am Jamie.
Aaron: You know, Jamie, I was thinking about how most of us have this huge blank space in our heads where our earliest childhood memories should be. I can’t remember anything before I was three or four. Most parents just accept that "infantile amnesia" is part of growing up, but I saw some research recently that suggests this might work differently for neurodivergent individuals. It really caught my eye because it feels so fundamental to how we experience the world.
Jamie: It really is. That research from Tomás Ryan’s team at Trinity College Dublin is fascinating because it uses a mouse model to look at what’s happening biologically. They looked at "maternal immune activation," which is basically when the mother’s immune system is triggered during pregnancy. In these cases, the male offspring didn't experience that typical infantile amnesia. They actually retained memories that usually would have been "pruned" or forgotten.
Aaron: Wait, so instead of forgetting, their brains are holding onto everything? That sounds like it could be quite overwhelming. I mean, we usually think of memory as a good thing, but is there a downside to not being able to filter out those early, perhaps less useful, memories?
Jamie: That’s the big question. The researchers found that these mice had a higher density of dendritic spines—those are the little connections where neurons talk to each other—and more active memory cells in a part of the brain called the dentate gyrus. It’s almost like the "forgetting" mechanism, which is actually a very active and necessary process in a developing brain, isn't clicking into gear properly. They pointed to microglia, which are the brain's resident immune cells, as the key players here.
Aaron: I’ve heard you mention microglia before. They are like the brain’s "gardeners," right? Trimming the hedges?
Jamie: Exactly. They prune away the excess connections to make the brain more efficient. If they aren't doing that pruning, or if they are focused on something else because of that early immune trigger, the "physical traces" of those early memories—what scientists call engrams—stay accessible. It’s a shift in how we think about autism-related traits; instead of seeing a "deficit," this study describes it more as an "excess" of memory retention.
Aaron: That’s a powerful shift in perspective. But it also makes me wonder about how we identify these differences in the first place. If the brain is developing on this unique trajectory, we should be noticing it, right? But then I look at the recent data from Sweden about how we diagnose boys versus girls, and it seems like we are missing a huge part of the picture for a long time.
Jamie: That connects perfectly. We’ve historically seen autism as something that primarily affects boys, with those 3-to-1 or 4-to-1 ratios often cited. But this massive Swedish study following nearly three million people shows that by the time they hit age 20, that ratio narrows down to almost 1.2-to-1.
Aaron: That is a staggering change. If I’m a parent of a young girl, and the doctor says, "Well, the stats say it's unlikely," but then by age 20 the stats say it's almost 50/50... that tells me we aren't looking for the right things in girls early on.
Jamie: Precisely. The research suggests that girls often have more advanced language skills or can maintain eye contact better in early childhood, which are the traditional "markers" clinicians look for. Plus, there’s the concept of masking or camouflaging—basically working incredibly hard to mimic social peers. As life gets more complex in the teenage years, that "mask" becomes much heavier and harder to maintain, which is why we see this huge spike in diagnoses for girls between ages 15 and 19.
Aaron: It’s like the social demands finally outpace the person’s ability to compensate. I also noticed the study mentioned "diagnostic overshadowing," where a girl might be diagnosed with anxiety or depression, and the underlying neurodivergence is completely missed. It makes me feel for those families who spent years trying to figure out why their child was struggling, only to get an answer a decade later.
Jamie: It highlights how much our "typical" definitions are based on a very specific profile. And when the research or the diagnostic tools are flawed, it creates this ripple effect. We actually saw a high-profile example of this recently with a retracted study regarding leucovorin, or folinic acid, as a treatment for autism.
Aaron: I remember seeing headlines about that a while back. A lot of parents were hopeful about it. What happened to make the journal pull the study?
Jamie: It was a mix of things. Other researchers noticed inconsistencies in the data tables—basically, the numbers didn't add up. But more importantly, the study used the Childhood Autism Rating Scale, or CARS, to measure "improvement." Experts point out that CARS was designed to help give a diagnosis, not to measure small changes in behavior over a short period. It’s like trying to use a ruler to measure the temperature; it’s just the wrong tool for the job.
Aaron: That’s so frustrating for families. You see a study in a medical journal, you think it’s been vetted, and then you find out the foundation was shaky. It makes it so hard to know who to trust, especially when you’re just trying to help your child.
Jamie: It really emphasizes why we need a high bar for scientific integrity. And speaking of trust and where the field is going, there’s been a lot of conversation lately about the IACC in the US—the Interagency Autism Coordinating Committee. They basically advise the government on where research money should go and what the national strategy should be.
Aaron: Right, and they just appointed a whole new group of people. I’ve heard there’s some concern from the advocacy community about these new members.
Jamie: There is. For the first time, there are no returning members, which means a lot of institutional knowledge is just gone. But the bigger concern for many is the drop in representation. The number of autistic self-advocates on the committee fell from seven down to just two. People are worried that the focus might shift away from things like "quality of life" and "community support" and move back toward looking for a "cure," or even worse, giving a platform to theories that have been scientifically debunked, like the vaccine link.
Aaron: It feels like a step backward if the people who actually live the experience aren't at the table. If you're a parent or an autistic adult, you want to know that the people making the big decisions actually understand the day-to-day reality, not just the theories.
Jamie: Exactly. Whether it's the biology of memory in mice, the way we're catching up on diagnosing girls, or the ethics of how research is funded, it all comes back to the same thing: we need to be really careful and really inclusive. The science is moving fast, and it’s complicated, but we have to make sure it’s serving the people it’s actually about.
Aaron: Well said, Jamie. It’s a lot to process, and as always, it feels like we have as many new questions as we do answers. But that’s why we keep having these conversations.
Jamie: It is. It’s about staying curious but also staying grounded in the data we do have.
Aaron: Thank you for walking through this with me today. For those of you listening, we’ve included the summaries of these articles and the original links on our episode page. You can find all the details there if you want to dive deeper into any of these topics.
Jamie: Thanks for joining us. We’ll see you next time.
Aaron: Goodbye everyone.
References
- Microglia implicated in infantile amnesia
- Sex bias in autism drops as age at diagnosis rises
- Time trends in the male to female ratio for autism incidence
- Concerns over diversity and scientific focus in IACC appointments
- Publicity vs. scientific belief in autism drug testing
- Maternal immune activation in mice reduces infantile amnesia